A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

December 31, 2009

Conditions
Acute Myeloid LeukemiaLeukemiaMyelodysplastic SyndromeAMLMDS
Interventions
DRUG

AC220

Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.

Trial Locations (5)

35294

University of Alabama at Birmingham, Birmingham

68198

University of Nebraska Medical Center, Omaha

77030

MD Anderson Cancer Center, Houston

Unknown

Chemotherapy and Immunotherapy Clinic, T'Bilisi

Hematology and Chemotherapy Clinic, T'bilisi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY